117 related articles for article (PubMed ID: 23978030)
1. [Can chronic myeloid leukemia be cured by tyrosine kinase inhibitor?].
Li MQ; Liu ZG
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):725-8. PubMed ID: 23978030
[No Abstract] [Full Text] [Related]
2. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
3. [III. Chronic myeloid leukemia-effectiveness of second generation tyrosine kinase inhibitors for first line treatment of chronic myeloid leukemia-].
Takahashi N
Gan To Kagaku Ryoho; 2012 May; 39(5):743-6. PubMed ID: 22701901
[No Abstract] [Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
5. Chronic myeloid leukemia: reversing the chronic phase.
Goldman JM
J Clin Oncol; 2010 Jan; 28(3):363-5. PubMed ID: 20008612
[No Abstract] [Full Text] [Related]
6. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Quintás-Cardama A; Kantarjian H; Cortes J
N Engl J Med; 2007 Oct; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
[No Abstract] [Full Text] [Related]
7. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
[No Abstract] [Full Text] [Related]
8. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
9. TKIs and transplant for chronic myeloid leukemia.
Litzow MR
Leuk Res; 2010 Feb; 34(2):137-8. PubMed ID: 19651441
[No Abstract] [Full Text] [Related]
10. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
Zámečníkova A
Expert Rev Hematol; 2010 Feb; 3(1):45-56. PubMed ID: 21082933
[TBL] [Abstract][Full Text] [Related]
11. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
[TBL] [Abstract][Full Text] [Related]
12. [Novel therapeutic approach of Ph-positive leukemia: combination of tyrosine kinase inhibitors with other targeted drugs].
Tauchi T
Rinsho Ketsueki; 2013 Jun; 54(6):559-67. PubMed ID: 23823095
[No Abstract] [Full Text] [Related]
13. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
Deininger MW; Manley P
Leuk Res; 2012 Mar; 36(3):253-61. PubMed ID: 21996558
[TBL] [Abstract][Full Text] [Related]
14. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
15. Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy.
Jalkanen SE; Vakkila J; Kreutzman A; Nieminen JK; Porkka K; Mustjoki S
Exp Hematol; 2011 Jan; 39(1):102-113.e1. PubMed ID: 20869423
[TBL] [Abstract][Full Text] [Related]
16. [Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
Nasr R; Bazarbachi A
Pathol Biol (Paris); 2012 Aug; 60(4):239-45. PubMed ID: 22743097
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
Jiménez-Velasco A; Barrios M; Alcalá M; Heiniger AI
J Clin Oncol; 2010 Jun; 28(18):e310; author reply e311. PubMed ID: 20479423
[No Abstract] [Full Text] [Related]
18. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
[TBL] [Abstract][Full Text] [Related]
19. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Rodrigues MS; Sattler M
J Natl Cancer Inst; 2007 May; 99(9):662-3. PubMed ID: 17470729
[No Abstract] [Full Text] [Related]
20. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
